^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:TheraCIM (nimotuzumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Int J Oncol
    Title:

    Nimotuzumab, an EGFR-targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma

    Published date:
    04/23/2020
    Excerpt:
    These results suggest that nimotuzumab combined with radiation may be an effective means to control recurrent esophageal squamous cell carcinoma with EGFR overexpression.
    DOI:
    10.3892/ijo.2020.4981